This MedLibrary.org supplementary page on Didrex is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. (July 2008) |
 |
|
|
Benzphetamine
|
|
| Systematic (IUPAC) name | |
| N-benzyl-N-methyl-1-phenyl-propan-2-amine | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C17H21N |
| Mol. mass | 239.355 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 75-99% |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Benzphetamine (brand name: Didrex) is an anti-obesity drug marketed under this brand in the USA by Pharmacia. Benzphetamine is used as a short term adjunct in management of exogenous obesity. It is closely related to amphetamine.
Pharmacology
Benzphetamine is a sympathomimetic amine, and is classified as an anorectic. The main function of this drug is to reduce hunger, which in turn reduces caloric intake.
Although the mechanism of action of the sympathomimetic appetite suppressants in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Amphetamine and related sympathomimetic medications (such as benzphetamine) are thought to stimulate the release of norepinephrine and/or dopamine from storage sites in nerve terminals in the lateral hypothalamic feeding center, thereby producing a decrease in appetite. This release is mediated by the binding of benzphetamine to centrally located adrenergic receptors. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.
Contraindications
Benzphetamine is contraindicated in patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyper-thyroidism, known hypersensitivity or idiosyncrasy to sympathomimetic amines, and glaucoma. Benzphetamine should not be given to patients who are in an agitated state or who have a history of drug abuse.
Controlled substance classification
Benzphetamine is unique in its classification as a Schedule III drug in the United States. (Most members of the amphetamine family are classified in the more highly-regulated Schedule II.) It's notable that benzphetamine is metabolized by the human body into amphetamine and methamphetamine metabolites, making it one of the very few drugs to undergo in vivo conversion to a substance of higher addiction and abuse potential. Benzphetamine itself does not have a such a high recreational abuse potential (Schedule III) because any administration route (ingested, insufflated, injected, etc.) would still have a sustained release due to the amount of time it would take the liver to metabolize it into amphetamine and methamphetamine.
Wikipedia content modification information:
- This page was last modified on 11 October 2008, at 06:42.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Didrex".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.